ImmunoTX Summit

Scheduled For: Tuesday, January 30th, 2018 View all Events

Date: January 30-31, 2018
Website: ImmunoTX Summit
Location: San Diego, CA










Advancing the Development of Personalized and Targeted Immune Therapies Utilizing CGI’s AntigenID™

Steve Siferd | Senior Director, BioPharma Business Development

January 30, 2018 | 1:50 pm PT

Abstract: Cancer is a genetic disease where tumors can accumulate somatic mutations which can alter downstream protein expression.  These altered proteins, when presented on the surface of a tumor cell can be recognized by T cells eliciting an anti-tumor immune response.  Historically, identifying tumor-specific mutant antigens was a difficult and protracted process.  By leveraging NGS with advanced computational analysis, CGI has created an integrated neoantigen pipeline to both identify novel expressed mutations and algorithmically estimate the binding affinity of the translated protein to the major histocompatibility complex haplotypes encoded by each genome.  Our AntigenID™ workflow can be utilized to both characterize overall somatic mutation burden and neoantigen burden, and validate predicted epitopes as a precursor to designing novel therapeutic agents.




Experiences & Perspectives on Real Life Application of Immunotherapies

Panel Moderator: Kamala Maddali, DVM, PhD | VP Biopharma Collaborations & Companion Diagnostics

January 31, 2018 | 12:20 pm PT

* sponsor

[formidable id=12 title=true description=true]